Free tool
FAERS Monitor: Incruse Ellipta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205382 or its brand name (Incruse Ellipta, Umeclidinium Bromide). Reports on generic versions are filed under their own applications.
Reports
9,060
Serious
4,828
53% of reports
Hospitalization
2,445
Death reported
661
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,437
- drug ineffective781
- cough735
- asthma640
- pneumonia578
- wrong technique in device usage process547
- chronic obstructive pulmonary disease420
- fatigue392
- product dose omission issue354
- death344
- wheezing341
- headache334
- off label use329
- malaise327
- nausea301
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 99 |
| 2016 | 636 |
| 2017 | 870 |
| 2018 | 1,173 |
| 2019 | 1,241 |
| 2020 | 1,186 |
| 2021 | 767 |
| 2022 | 672 |
| 2023 | 622 |
| 2024 | 679 |
| 2025 | 584 |
| 2026 | 520 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,099 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wrong technique in device usage processSignal | 547 | 27.5 | 25.3 | 13,808 |
| chronic obstructive pulmonary diseaseSignal | 420 | 18.8 | 17.1 | 7,033 |
| wheezingSignal | 341 | 13.4 | 12.1 | 3,896 |
| asthmaSignal | 640 | 13.2 | 12.3 | 7,212 |
| coughSignal | 735 | 6.1 | 5.7 | 3,161 |
| dyspnoeaSignal | 1,437 | 5.9 | 5.6 | 5,997 |
| pneumoniaSignal | 578 | 4.2 | 3.8 | 1,398 |
| product dose omission issueSignal | 354 | 2.8 | 2.5 | 412 |
| malaise | 327 | 1.7 | 1.6 | 102 |
| drug ineffective | 781 | 1.4 | 1.3 | 85 |
| headache | 334 | 1.2 | 1.1 | 15 |
| fatigue | 392 | 1.2 | 1.1 | 10 |
| death | 344 | 0.9 | 0.8 | 2 |
| nausea | 301 | 0.9 | 0.8 | 5 |
| off label use | 329 | 0.9 | 0.8 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.